Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Brief: Oncolytics reports additional data from phase II study of Reolysin

Aug 10 (Reuters) - Oncolytics Biotech Inc  ONC.TO  
    * Oncolytics Biotech Inc. reports additional data from 
randomized phase II study of Reolysin in non-small cell lung 
cancer 
    * Study demonstrates statistically significant improvement 
in progression free survival in female patients with 
Adenocarcinoma 
    * Based on findings from IND 211, intends to include 
preselection of patients using genetic screening in future study 
protocols 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nCNWjBzD9a 
Further company coverage:  ONC.TO  
 
 ((bangalore.newsroom@thomsonreuters.com;))

Recent news on Oncolytics Biotech

See all news